| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Transcode Therapeutics Inc (NASDAQ:RNAZ) shares are trading lower by 62% to $0.30 during Tuesday’s session after the company announced pricing of its public offering.
The public offering of 10 million shares of its common stock will be at $0.30 per share, aiming to raise $3 million before deducting expenses. The offering is set to close on July 24, pending usual conditions.
The funds will be used for product development, including clinical trials for TTX-MC138, their lead therapeutic candidate, and related studies as well as for general corporate purposes.
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.
RNAZ has a 52-week high of $128.00 and a 52-week low of $0.30.
Posted In: RNAZ
